Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-11-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于作废部分已授予尚未归属的2020年限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding the cancellation of certain unvested restricted stocks granted under the 2020 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and compliance with relevant laws and regulations. The content focuses on changes related to stock incentives and does not contain financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or investor presentation. It is a regulatory announcement about share-based compensation adjustments, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS) because it concerns cancellation of unvested restricted stock rather than new issuance or buyback. The document length is about 4042 characters, which is relatively short and typical for an announcement rather than a full report. Therefore, the classification is Regulatory Filings (RNS).
2023-11-13 Chinese
美迪西：第三届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Shanghai Medicilon Inc. It details the meeting date, attendance, and specific agenda items related to the company's 2020 restricted stock incentive plan, including approval of stock vesting, adjustments to grant quantities and prices, and cancellation of some unvested shares. The document references compliance with relevant laws and regulations and provides voting results. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is a formal announcement of board/management decisions related to stock incentive plans, which falls under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2023-11-13 Chinese
北京安理（上海）律师事务所关于上海美迪西生物医药股份有限公司2020年限制性股票激励计划授予数量及授予价格调整、第三个归属期归属条件成就暨部分限制性股票作废事项的法律意见书
Regulatory Filings
2023-11-13 Chinese
美迪西：2020年限制性股票激励计划第三个归属期符合归属条件的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the third vesting period of a 2020 restricted stock incentive plan by Shanghai Medicilon Inc. It includes specifics about the stock grant, vesting conditions, performance targets, board and supervisory approvals, legal opinions, and detailed lists of beneficiaries and their stock allocations. The content focuses on the stock incentive plan's implementation, vesting results, and compliance with regulatory requirements. It is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is also not a call transcript, earnings release, or capital financing update. The document is a regulatory announcement about the stock incentive plan's vesting results and related approvals, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Remuneration Information or Board/Management Information exactly, but is a formal regulatory disclosure about stock incentives and their vesting.
2023-11-13 Chinese
美迪西：第三届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Shanghai Medicilon Inc. It includes multiple agenda items such as approval of stock incentive plans, adjustments to stock grant quantities and prices, cancellation of unvested restricted stock, and approval of a share repurchase plan. The document is not a full financial report but rather a formal announcement of board decisions related to management and corporate actions. It specifically details board meeting procedures, voting results, and references to related announcements on the stock exchange website. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length is 2503 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2023-11-13 Chinese
美迪西：独立董事关于第三届董事会第十九次会议相关事项的独立意见
Regulatory Filings
2023-11-13 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.